Patents by Inventor Michael Peel

Michael Peel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclophilin inhibitors and uses thereof
    Patent number: 12522634
    Abstract: Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, in particular diseases or conditions associated with cellular injury or cell death, such as organ injury or organ failure, which can be caused by a number of different reasons, such as ischemia or ischemia reperfusion injury, toxins, infection or mechanical trauma.
    Type: Grant
    Filed: June 26, 2024
    Date of Patent: January 13, 2026
    Assignee: Farsight Medical Technology (Shanghai) Co., Ltd.
    Inventors: Ching-Pong Mak, Hans Fliri, Fashu Ma, Michael Peel
  • Prevention and treatment of organ injuries
    Patent number: 12465629
    Abstract: The invention provides for Compound I or a pharmaceutically acceptable salt thereof (I) for use in the prevention and/or treatment of an organ injury, or a condition associated with an organ injury, in a subject diagnosed with, or suffering from an infection.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: November 11, 2025
    Assignee: Farsight Medical Technology (Shanghai) Co., Ltd.
    Inventors: Ching-Pong Mak, Fashu Ma, Dong Xiao, Michael Peel, Hans Fliri
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20250243219
    Abstract: The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in the treatment or prevention of diseases that are caused by (1) cell death due to various causes and (2) inflammation. Such diseases can affect all parts of the body, including the central and peripheral nervous systems, all organs and tissues, the muscles, the vasculature and the bones.
    Type: Application
    Filed: May 19, 2023
    Publication date: July 31, 2025
    Inventors: Victoria Alexandra Steadman, David Kenneth Dean, Steven Stanway, Antoinette Wilson, Andrew Keats, Michael Peel
  • CYCLOSPORIN ANALOGUES AND USES THEREOF
    Publication number: 20250177477
    Abstract: A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1: or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from Hor C1-C4 alkyl, wherein R1 and R2 may be joined together to form a C3-C5 heteroalkyl ring.
    Type: Application
    Filed: October 2, 2024
    Publication date: June 5, 2025
    Inventors: Michael PEEL, Li Zeng, Shengqiang Yu
  • CYCLOPHILIN INHIBITORS AND USES THEREOF
    Publication number: 20240352074
    Abstract: Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, in particular diseases or conditions associated with cellular injury or cell death, such as organ injury or organ failure, which can be caused by a number of different reasons, such as ischemia or ischemia reperfusion injury, toxins, infection or mechanical trauma.
    Type: Application
    Filed: June 26, 2024
    Publication date: October 24, 2024
    Inventors: Ching-Pong Mak, Hans Fliri, Fashu Ma, Michael Peel
  • COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR
    Publication number: 20240293411
    Abstract: The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
    Type: Application
    Filed: February 1, 2024
    Publication date: September 5, 2024
    Inventors: Michael Peel, Paul Smith
  • Cyclophilin inhibitors and uses thereof
    Patent number: 12060440
    Abstract: Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, such as organ injury or organ failure.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: August 13, 2024
    Assignee: FARSIGHT MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Ching-Pong Mak, Hans Fliri, Fashu Ma, Michael Peel
  • Combination therapy comprising JAK pathway inhibitor and rock inhibitor
    Patent number: 11918581
    Abstract: The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: March 5, 2024
    Assignee: Incyte Corporation
    Inventors: Michael Peel, Paul Smith
  • CYCLOPHILIN INHIBITORS AND USES THEREOF
    Publication number: 20230203099
    Abstract: Provided are compounds as defined by Formula 1 and uses thereof for the prevention or treatment of disease or conditions such as organ injury or organ failure.
    Type: Application
    Filed: March 25, 2021
    Publication date: June 29, 2023
    Inventors: Ching-Pong Mak, Hans Fliri, Fashu Ma, Michael Peel
  • PREVENTION AND TREATMENT OF ORGAN INJURIES
    Publication number: 20230181680
    Abstract: The invention provides for Compound I or a pharmaceutically acceptable salt thereof (I) for use in the prevention and/or treatment of an organ injury, or a condition associated with an organ injury, in a subject diagnosed with, or suffering from an infection.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 15, 2023
    Inventors: Ching-Pong Mak, Fashu Ma, Dong Xiao, Michael Peel, Hans Fliri
  • CYCLOPHILIN INHIBITORS AND USES THEREOF
    Publication number: 20230110497
    Abstract: Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, such as organ injury or organ failure.
    Type: Application
    Filed: September 16, 2022
    Publication date: April 13, 2023
    Inventors: Ching-Pong Mak, Hans Fliri, Fashu Ma, Michael Peel
  • COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR
    Publication number: 20220226327
    Abstract: The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
    Type: Application
    Filed: January 10, 2022
    Publication date: July 21, 2022
    Inventors: Michael Peel, Paul Smith
  • CYCLOSPORIN ANALOGUES AND USES THEREOF
    Publication number: 20220072093
    Abstract: A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1: or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 alkyl, wherein R1 and R2 may be joined together to form a C3-C5 heteroalkyl ring.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 10, 2022
    Inventors: Michael Peel, Li Zeng, Shengqiang Yu
  • Macrocycles
    Patent number: 10738084
    Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 11, 2020
    Assignee: Sentry Therapeutics Limited
    Inventors: Michael Peel, Andrew Scribner, Koichi Watashi, Satomi Shimura
  • CYCLOSPORIN ANALOGUES AND USES THEREOF
    Publication number: 20200171122
    Abstract: A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1: or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 alkyl, wherein R1 and R2 may be joined together to form a C3-C5 heteroalkyl ring.
    Type: Application
    Filed: July 23, 2018
    Publication date: June 4, 2020
    Inventors: Michael Peel, Li Zeng, Shengqiang Yu
  • NOVEL MACROCYCLES
    Publication number: 20180186836
    Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 5, 2018
    Applicant: Cypra;os Limited
    Inventors: Michael Peel, Andrew Scribner, Koichi Watashi, Satomi Shimura
  • Antifungal agents
    Patent number: 7863465
    Abstract: The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-?-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 4, 2011
    Assignees: Merck Sharp & Dohme Corp., Scynexis, Inc.
    Inventors: James M. Balkovec, Frances Aileen Bouffard, Bruno Tse, James Dropinski, Dongfang Meng, Mark L. Greenlee, Michael Peel, Weiming Fan, Ahmed Mamai, Hao Liu, Keqaing Li
  • ISOQUINOLINE COMPOUNDS
    Publication number: 20100093790
    Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
    Type: Application
    Filed: December 16, 2009
    Publication date: April 15, 2010
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
  • ISOQUINOLINE COMPOUNDS
    Publication number: 20090069371
    Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
    Type: Application
    Filed: November 20, 2008
    Publication date: March 12, 2009
    Applicant: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
  • Isoquinoline compounds
    Patent number: 7470787
    Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: December 30, 2008
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Claire Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel